KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares IssuedShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Share-based Compensation (2016 - 2025)

Emergent BioSolutions' Share-based Compensation history spans 16 years, with the latest figure at $5.3 million for Q4 2025.

  • For Q4 2025, Share-based Compensation rose 23.26% year-over-year to $5.3 million; the TTM value through Dec 2025 reached $16.2 million, down 10.0%, while the annual FY2025 figure was $16.2 million, 10.0% down from the prior year.
  • Share-based Compensation reached $5.3 million in Q4 2025 per EBS's latest filing, up from $4.8 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $12.3 million in Q2 2022 to a low of $1.5 million in Q1 2025.
  • Average Share-based Compensation over 5 years is $7.2 million, with a median of $6.4 million recorded in 2023.
  • The largest YoY upside for Share-based Compensation was 108.7% in 2025 against a maximum downside of 74.58% in 2025.
  • A 5-year view of Share-based Compensation shows it stood at $10.1 million in 2021, then increased by 15.84% to $11.7 million in 2022, then tumbled by 65.81% to $4.0 million in 2023, then rose by 7.5% to $4.3 million in 2024, then increased by 23.26% to $5.3 million in 2025.
  • Per Business Quant, the three most recent readings for EBS's Share-based Compensation are $5.3 million (Q4 2025), $4.8 million (Q3 2025), and $4.6 million (Q2 2025).